1. Home
  2. IOVA vs BATRA Comparison

IOVA vs BATRA Comparison

Compare IOVA & BATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IOVA
  • BATRA
  • Stock Information
  • Founded
  • IOVA 2007
  • BATRA 1991
  • Country
  • IOVA United States
  • BATRA United States
  • Employees
  • IOVA N/A
  • BATRA N/A
  • Industry
  • IOVA Biotechnology: Biological Products (No Diagnostic Substances)
  • BATRA Broadcasting
  • Sector
  • IOVA Health Care
  • BATRA Industrials
  • Exchange
  • IOVA Nasdaq
  • BATRA Nasdaq
  • Market Cap
  • IOVA 2.6B
  • BATRA 2.6B
  • IPO Year
  • IOVA N/A
  • BATRA N/A
  • Fundamental
  • Price
  • IOVA $5.91
  • BATRA $40.28
  • Analyst Decision
  • IOVA Strong Buy
  • BATRA Strong Buy
  • Analyst Count
  • IOVA 9
  • BATRA 2
  • Target Price
  • IOVA $23.33
  • BATRA $53.50
  • AVG Volume (30 Days)
  • IOVA 9.1M
  • BATRA 48.3K
  • Earning Date
  • IOVA 02-26-2025
  • BATRA 02-26-2025
  • Dividend Yield
  • IOVA N/A
  • BATRA N/A
  • EPS Growth
  • IOVA N/A
  • BATRA N/A
  • EPS
  • IOVA N/A
  • BATRA N/A
  • Revenue
  • IOVA $90,858,000.00
  • BATRA $678,378,000.00
  • Revenue This Year
  • IOVA $13,758.71
  • BATRA $10.38
  • Revenue Next Year
  • IOVA $171.20
  • BATRA $5.23
  • P/E Ratio
  • IOVA N/A
  • BATRA N/A
  • Revenue Growth
  • IOVA 12751.20
  • BATRA 5.31
  • 52 Week Low
  • IOVA $5.62
  • BATRA $38.90
  • 52 Week High
  • IOVA $18.33
  • BATRA $46.65
  • Technical
  • Relative Strength Index (RSI)
  • IOVA 28.87
  • BATRA 47.58
  • Support Level
  • IOVA $5.62
  • BATRA $39.32
  • Resistance Level
  • IOVA $6.44
  • BATRA $40.69
  • Average True Range (ATR)
  • IOVA 0.45
  • BATRA 0.64
  • MACD
  • IOVA -0.10
  • BATRA 0.06
  • Stochastic Oscillator
  • IOVA 11.46
  • BATRA 55.87

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

About BATRA Atlanta Braves Holdings Inc. Series A

Atlanta Braves Holdings Inc is a holding company. It operates through its wholly-owned subsidiary, which is the owner and operator of the Atlanta Braves Major League Baseball Club and the mixed-use real estate development, The Battery Atlanta, and is the operator of the Atlanta Braves Major League Baseball Club's stadium, Truist Park. The company predominantly derives revenue related to the Braves baseball franchise and Truist Park from ticket sales, concessions, local broadcasting rights, advertising sponsorships, suites and premium seat fees, retail and licensing revenue, shared MLB revenue streams, including national broadcasting rights and licensing, and other sources. The company's reportable segments include, baseball which generates key revenue, and mixed-use development.

Share on Social Networks: